Biperiden

Biperiden

Clinical data
Pregnancy category	AU: B2 US: C (Risk not ruled out)
Routes of administration	Oral, IM, IV
ATC code	N04AA02 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	33 ± 5% (oral)
Protein binding	60%
Metabolism	Hepatic hydroxylation
Elimination half-life	18 to 24 hours
Excretion	Renal
Identifiers
IUPAC name 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-(1-piperidyl) propan-1-ol
CAS Number	514-65-8
PubChem CID	2381
DrugBank	APRD00725
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C21H29NO
Molar mass	311.461 g/mol

WikiDoc Resources for Biperiden
Articles
Most recent articles on Biperiden Most cited articles on Biperiden Review articles on Biperiden Articles on Biperiden in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Biperiden Images of Biperiden Photos of Biperiden Podcasts & MP3s on Biperiden Videos on Biperiden
Evidence Based Medicine
Cochrane Collaboration on Biperiden Bandolier on Biperiden TRIP on Biperiden
Clinical Trials
Ongoing Trials on Biperiden at Clinical Trials.gov Trial results on Biperiden Clinical Trials on Biperiden at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Biperiden NICE Guidance on Biperiden NHS PRODIGY Guidance FDA on Biperiden CDC on Biperiden
Books
Books on Biperiden
News
Biperiden in the news Be alerted to news on Biperiden News trends on Biperiden
Commentary
Blogs on Biperiden
Definitions
Definitions of Biperiden
Patient Resources / Community
Patient resources on Biperiden Discussion groups on Biperiden Patient Handouts on Biperiden Directions to Hospitals Treating Biperiden Risk calculators and risk factors for Biperiden
Healthcare Provider Resources
Symptoms of Biperiden Causes & Risk Factors for Biperiden Diagnostic studies for Biperiden Treatment of Biperiden
Continuing Medical Education (CME)
CME Programs on Biperiden
International
Biperiden en Espanol Biperiden en Francais
Business
Biperiden in the Marketplace Patents on Biperiden
Experimental / Informatics
List of terms related to Biperiden

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Biperiden is an antiparkinsonian agent of the anticholinergic type. The original brand name - still existing - is Akineton®, manufactured by BASF/Knoll Pharma. Generics are available worldwide.

Pharmacokinetics

The oral bioavailability is only 33 +/- 5% due to extensive first-pass metabolization. In young, healthy volunteers peak plasma concentrations following an oral single dose of 4mg in immediate release form are reached after 1.5 hours. The elimination half-life has been determined as 18.4 hours, and may be prolonged in geriatric patients. After IV dosing of 4mg the elimination half-life is approximately 24 hours.

Pharmacology

Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervated (e.g. cardiovascular and visceral organs). It also has a prominent central blocking effect on M1 receptors.

Uses

Biperiden is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arteriosclerotic). It seems to exert better effects in the postencephalitic and idiopathic than in the arteriosclerotic type. Biperiden is also commonly used to improve parkinsonian signs and symptoms related to antipsychotic drug therapy. It relieves muscle rigidity, reduces abnormal sweating and salivation, improves abnormal gait, and to lesser extend, tremor.

Contraindications and cautions

• Hypersensitivity to biperiden
• Narrow angle glaucoma
• Ileus
• Caution : Patients with obstructive diseases of the urogenital tract, patients with a known history of seizures and those with potentially dangerous tachycardia

Special patient groups

Pregnancy and lactation

• Pregnancy : In animal studies biperiden had no embryo- or fetotoxic effects. There is no sufficient clinical data on pregnant women. The drug should therefore be used cautiously during pregnancy.

• Lactation : Biperiden is found in the milk of lactating women. No sufficient clinical data exists regarding effects for the newborns. Additionally, biperiden may decrease maternal milk production. It is therefore recommended that biperiden is not used during lactation.

Pediatric patients

Children and adolescents aged 1 year and older may be treated. The clinical experience is mainly on the shortterm treatment of acute drug induced dystonic reactions. Doses should be reduced according to the weight of the patients.

Side effects

Dose-dependent side effects are frequent. Particularly geriatric patients may react with confusional states or develop delirium.

• CNS : Drowsiness, vertigo, headache, and dizziness are frequent. With high doses nervousness, agitation, anxiety, delirium, and confusion are noted. Biperiden may be abused due to a short acting mood-elevating and euphoriant effect. The normal sleep architecture may be altered (REM sleep depression). Biperiden may lower the seizure-threshold. Some instances of dementia have been noted to correllate with chronic administration of anticholinergic medications such as Biperiden for Parkinson's disease.
• Peripheral side effects : Blurred vision, dry mouth, impaired sweating, abdominal discomfort, and obstipation are frequent. Tachycardia may be noted. Allergic skin reactions may occur. Parenteral use may cause orthostatic hypotension.
• Eyes : Biperiden causes mydriasis with or without photophobia. It may precipitate narrow angle glaucoma.

Interactions

• Other anticholinergic drugs (e.g. spasmolytics, antihistamines, TCAs) : Side effects of biperiden may be increased.
• Quinidine : Increased anticholinergic action (particular on AV conduction).
• Antipsychotics : Long term use of biperiden may mask or increase the risk of tardive dyskinesia.
• Pethidine (meperidine) : Central effects and side effects of pethidine may be increased.
• Metoclopramide : Action of metoclopramide is decreased.
• Alcohol : Risk of serious intoxication.

Dosage

Strictly individual. Oral, and in some countries, IV and IM use is possible. The usual oral daily doses are between 2 and 16mg. If possible, patients should be started with a low initial dose which is increased slowly.

Overdose

Biperiden mimics an atropine intoxication with mydriasis, dryness of mucous membranes, red face, atonic states of bowels and bladder, and hyperthermia in high doses. Central consequences are agitation, confusion, and hallucinations. An untreated overdose may be fatal, particular in children. Premortal signs are respiratory depression and cardiac arrest. A specific antagonist is physostigmine which combines a peripheral and a central action. Carbachol can be used to treat atonic bowels and bladder. The vital functions should be monitored and stabilized. It may be necessary to treat hyperthermia with cooling blankets.

History

Biperiden was synthesized by the German chemist W. Klavehn from Knoll AG, Germany. In March 1953 a patent was applied for in Germany and subsequently in many other countries.

References

• AHFS database online
• Scientific Information on Akineton (Swiss)
• Arnd Barocka, Psychopharmakotherapie in Klinik und Praxis, Schattauer-Verlag , 1998 (German language)
• Albers, Lawrence (2001–2002). Handbook of Psychiatric Drugs. Laguna Hills, California: Current Clinical Strageties. CS1 maint: Date format (link)